Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1981 twice daily for 61/2 days · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD1981 100 mg twice daily for 6 ½ days |
| Name | Type | Description |
|---|---|---|
| AZD1981 100 mg twice daily for 61/2 days | DRUG | 100 mg tablets |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * A minimum of 6 months documented history of asthma * Be a non-smoker or ex-smoker who has stopped smoking for \>6 months prior to Visit 1 (pre-entry) Exclusion Criteria: * Any clinically significant disea...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
AZD1981 twice daily for 61/2 days is an investigational small molecule developed by AstraZeneca PLC for asthma. It was studied in a Phase 1 pharmacokinetics trial in adolescents. The dosing description refers to 100 mg taken twice daily over a six and a half day period.
AZD1981 100 mg twice daily for 61/2 days was studied in asthma. The Phase 1 trial enrolled adolescents with asthma in Sweden, not healthy volunteers. AZD1981 twice daily for 61/2 days and AZD1981 100 mg twice daily for 61/2 days are the same investigational regimen.
AZD1981 twice daily for 61/2 days targets PTGDR2, also known as the DP2 receptor, and acts as an antagonist at that receptor. Antagonism of PTGDR2 is the intended mechanism of this small molecule in asthma.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of AZD1981 twice daily for 61/2 days. The compound is an AstraZeneca small molecule studied for respiratory indications including asthma.
AZD1981 twice daily for 61/2 days is in Phase 1 development and is investigational. It has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
AZD1981 twice daily for 61/2 days was studied in NCT01196689, titled Pharmacokinetics in Adolescents. That Phase 1 trial was completed, enrolled 21 participants with asthma in Sweden, included males aged 12 years and older, and was uncontrolled without randomization or blinding.